CBAY Archives - Spark Newswire

1 minute read

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

February 13, 3:05 PM

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.

CBAY

2 minute read

Fear & Greed Index Remains In ‘Extreme Greed’ Zone Ahead Of Inflation Data; Dow Hits Record high

By Avi Kapoor

February 13, 4:43 AM

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session.

2 minute read

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B

By Avi Kapoor

February 12, 1:30 PM

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500 also rose, gaining, 0.30% to 5,041.87.

ANTX

2 minute read

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday

By Avi Kapoor

February 12, 11:22 AM

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

ALLO

2 minute read

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics

By Benzinga Insights

February 12, 11:10 AM

Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in…

CBAY

2 minute read

Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B

By Vandana Singh

February 12, 10:22 AM

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue growth.

CBAY

3 minute read

Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics For $32.50/Share Or A Total Equity Value Of $4.3B

By Benzinga Newsdesk

February 12, 9:31 AM

-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 ---- Seladelpar Phase 3 Data

CBAY